(Q39657872)

13 September 2017

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy (English)

1 reference

13 September 2017

chronic myeloid leukemia

0 references

1 reference

3

Hagop Kantarjian

1 reference

13 September 2017

2

Jorge Cortes

1 reference

13 September 2017

1

Xuelin Huang

1 reference

PMCID

3342429

13 September 2017

language of work or name

English

0 references

publication date

31 January 2012

1 reference

13 September 2017

1 reference

13 September 2017

118

1 reference

13 September 2017

12

1 reference

13 September 2017

3123-3127

1 reference

13 September 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Chronic myelogenous leukaemia (CML): an update

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Global cancer statistics, 2002

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

United States life tables, 2006.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342429

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22294282

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.26679

1 reference

13 September 2017

1 reference

13 September 2017

1 reference

PMCID

3342429